← GLP-1 receptor agonists × glycemic control

TrialJAMA2017

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Melanie Davies et al.PubMed ↗Full text ↗Publisher ↗

The primary results report of NCT01923181. Its numbers are set against the trial’s posted results below.

What the trial testedas reported · 1,106 people · 2017

No range given

Reported lower glycemic control, no range given

Doesn’t vote: same as the registry's posted result, which counts instead

−1.60percentage points

As reported

difference −1.6 %, no interval

Against the trial’s posted results

  • Same as the trial’s posted resultThis paper difference −1.60Posted, primary outcome difference −1.60 (−1.89 to −1.30), p <0.0001Change in HbA1c (Glycosylated Haemoglobin)

One number in the abstract

the abstract, start to end

… oral semaglutide vs placebo, -0.4% to -1.6%; P = .01 for 2.5 mg, <.001 for …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−1.6
GLP-1 receptor agonistsGlycemic control
1 / 3

218 papers cite itlatest 60 shown

2017
…
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01923181phase 2632 enrolled2013this paper is its primary report
Full record →Abstract, authors, funding and every citing paper · PMID 29049653